When does Eli Lilly’s tirzepatide patent expire?
Eli Lilly’s tirzepatide (Mounjaro/Zepbound) patent protection depends on the country and on the specific patent(s) covering different aspects of the drug (the molecule, formulations, and method-of-use claims). Patent terms also vary because of filing dates and possible adjustments like patent term extensions.
How long is the usual patent term for a drug like tirzepatide?
In most jurisdictions, a new drug’s key patents generally run for about 20 years from the earliest priority filing date, subject to extensions and withdrawals tied to regulatory timelines. That means the practical exclusivity window for tirzepatide can be longer than the basic term, but the exact end date is set by the particular patents in force in each country rather than by a single “one-size-fits-all” year.
What could extend or shorten the effective exclusivity window?
Even if a primary patent is near its scheduled end, exclusivity can persist through:
- Additional patents (for specific formulations, dosing, manufacturing, or use).
- Regulatory protections such as data exclusivity and marketing exclusivity (which are separate from patents and vary by country).
Conversely, exclusivity can end sooner if relevant patents are invalidated or limited by court decisions, or if the patent landscape changes through licensing or settlements.
If you tell me the country, can you give the exact year?
Yes. The expiration date you want is specific to where you’re asking (U.S., EU/UK, Canada, etc.) and whether you mean the “first relevant patent end” or the “last blocking exclusivity.” Share the country (and whether you mean Mounjaro, Zepbound, or tirzepatide broadly), and I’ll narrow it to the most relevant end date(s).